Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate is SL-325, a monoclonal antibody which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

	A	B	C	D
1	Symbol	Price	Change	Volume
2	STTK	$7.40	0.00%	987.53K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	STTK	$7.40	0%	987.53K
3
4
5
6

STTK

STTK

No Data Available

Get Shattuck Labs Inc. Data in Excel

Get Shattuck Labs Inc. Data in Excel